Coxetori 120mg

Tablet
Etoricoxib
Amulet Pharmaceuticals

Other Strength:
- Coxetori 60mg

Alternative:
- Tory 120mg
- Cox-E 120mg
- Vericox 120mg
- Riox 120mg
- Ecox 120mg
- Etovan 120mg
- Etoben 120mg
- Aroxia 120mg
- Setorib 120mg
- Ribox 120mg
- Recox 120mg



Coxetori
DESCRIPTION:
COXETORI (Etoricoxib) is a Non-Steroidal Anti-Inflammatory Drug (NSAID) that exhibits anti-inflammatory, analgesic and antipyretic activities. It is a potent, orally active, highly selective cyclooxygenase-2 (COX-2) inhibitor within and above the clinical dose range. COX-2 has been shown to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation and fever. Selective inhibition of COX-2 by Etoricoxib decreases these clinical signs and symptoms with decreased GI toxicity and without effects on platelet function.

COMPOSITION:
COXETORI 60 Tablet : Each film coated tablet contains Etoricoxib INN 60 mg.
COXETORI 120 Tablet : Each film coated tablet contains Etoricoxib INN 120 mg.

INDICATION:
COXETORI (Etoricoxib) is indicated for relief of pain and inflammation in –

* Osteoarthritis,

* Rheumatoid arthritis,

* Other chronic musculoskeletal disorders,

* Acute gout,

* Dysmenorrhoea, &

* Following dental surgery.

DOSAGE AND ADMINISTRATION:
Adult and adolescent over 16 years: Osteoarthritis, chronic musculoskeletal disorders & dysmenorrhoea: 60 mg, once daily. Pain following dental surgery & acute gout: 120 mg, once daily. Safety and effectiveness of Etoricoxib in paediatric patients have not been established.

CONTRAINDICATION & PRECAUTION:
Etoricoxib is contraindicated to patients with known hypersensitivity to Etoricoxib, patients with active peptic ulceration or gastro-intestinal (GI) bleeding, patients who have developed signs of asthma, acute rhinitis, nasal polyps, angioneurotic oedema or urticaria following the administration of acetylsalicylic acid or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), patient having inflammatory bowel disease, severe congestive heart failure, to children and adolescents under 16 years of age. In patients with advanced renal disease, treatment with it is not recommended. If therapy with it must be initiated in such patients, close monitoring of the patient’s renal function is advisable. It is advisable to rehydrate patients prior to starting therapy with it. The possibility of fluid retention, oedema or hypertension should be taken into consideration when it is used in patients with pre-existing oedema, hypertension, or heart failure. A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver function test has occurred, should be evaluated for persistently abnormal liver function tests. If persistently abnormal liver function tests (three times the upper limit of normal) are detected, it should be discontinued. It should be used with caution in patients who have previously experienced acute asthmatic attacks, urticaria, or rhinitis, which were precipitated by salicylates or non-selective cyclooxygenase inhibitors. It may mask fever, which is a sign of infection. The physician should be aware of this when using it in patients being treated for infection.

SIDE EFFECT:
Dry mouth, taste disturbance, mouth ulcers, flatulence, constipation, appetite and weight changes, chest pain, fatigue, paraesthesia, influenza-like syndrome & myalgia.

DRUG INTERACTION:
Oral anticoagulants, diuretics and ACE inhibitors, Acetylsalicylic acid, Cyclosporin and Tacrolimus, Lithium, Methotrexate, Oral, Contraceptives, Prednisone/Prednisolone, Digoxin, drugs metabolized by sulfotransferases (Ethinyl Estradiol), drugs metabolized by CYP isoenzymes, Ketoconazole, Rifampicin, and Antacids have interaction with Etoricoxib.

USE IN PREGNANCY AND LACTATION:
As with other drugs known to inhibit prostaglandin synthesis, use of it should be avoided in late pregnancy because it may cause premature closure of the ductus arteriosus. It should be used during the first two trimesters of pregnancy only if the potential benefit justifies the potential risk to the foetus. It is not known whether this drug is excreted in human milk.

STORAGE:
Store at a cool & dry place protected from light & moisture. Keep out of the reach of children.

HOW SUPPLIED:
COXETORI 60 Tablet : Box containing 3 x 10 tablets in Alu-pvc blister pack.
COXETORI 120 Tablet : Box containing 2 x10 tablets in Alu-pvc blister pack.

এই পাতাটি ৪২৯ বার দেখা হয়েছে

25th April
বিশ্ব ম্যালেরিয়া দিবস

বিশ্ব ম্যালেরিয়া দিবস প্রতি বছর ২৫ এপ্রিল পালিত হয়। এই দিবসটি ম্যালেরিয়া রোগ সম্পর্কে জনসচেতনতা বৃদ্ধি এবং এর বিরুদ্ধে প্রতিরোধমূলক ব্যবস্থা গ্রহণে উৎসাহ দেওয়ার জন্য পালন করা হয়। বিশ্ব স্বাস্থ্য সংস্থা (WHO) ২০০৭ সালে এই দিবসটি ঘোষণা করে। ম্যালেরিয়া একটি মশাবাহিত রোগ, যা Plasmodium পরজীবী দ্বারা ঘটে এবং Anopheles মশার মাধ্যমে ছড়ায়। বিশ্বজুড়ে প্রতিবছর লক্ষ লক্ষ মানুষ এই রোগে আক্রান্ত হয়, বিশেষ করে আফ্রিকা ও দক্ষিণ এশিয়ায়। এই দিবসে বিভিন্ন স্বাস্থ্য সচেতনতামূলক কর্মসূচি, প্রচারাভিযান এবং চিকিৎসা সংক্রান্ত উদ্যোগ নেওয়া হয় যাতে এই রোগ নির্মূলে কার্যকর পদক্ষেপ নেওয়া যায়। সকলের সহযোগিতায় ম্যালেরিয়া মুক্ত বিশ্ব সম্ভব।